
Anna Isotta Castrini
- Cardiologist, PhD fellow; MD
Anna Isotta Castrini, MD, is cardiologist and PhD fellow at last year at Department of Cardiology, OUS, Rikshospitalet. She is supervised by Prof. Kristina Haugaa, Dr. Øyvind Lie, MD, PhD and Dr. Mette Estensen MD, PhD. Inherited cardiomyopathies are the main topic of her PhD project, with focus on effect of pregnancy on disease’s penetrance and progression. With the research group, she published two important papers on the effect of pregnancy in arrhythmogenic cardiomyopathy and Lamin A/C cardiomyopathy, recently included in the European guidelines for management of cardiomyopathies. During her research fellowship, Dr. Castrini was awarded by “Best poster Price” during the Annual Symposium for Heart Research.
Dr. Castrini has a special interest for echocardiography and she is certified by the European Association
for Cardiovascular Imaging for trans-thoracic echocardiography in adults.
Publications 2025
DeepValve: The first automatic detection pipeline for the mitral valve in Cardiac Magnetic Resonance imaging
192 (Pt A), 110211
DOI 10.1016/j.compbiomed.2025.110211, PubMed 40311468
Disease Progression in Exercise-Induced Arrhythmogenic Cardiomyopathy Compared With Arrhythmogenic Right Ventricular Cardiomyopathy
18 (8), 853-863
DOI 10.1016/j.jcmg.2025.03.018, PubMed 40637652
Publications 2024
Prediction of severe ventricular arrhythmias in patients with mitral valve prolapse by exercise ECG
21 (11), 2339-2340
DOI 10.1016/j.hrthm.2024.04.076, PubMed 38663787
Stretch of the papillary insertion triggers reentrant arrhythmia: an in silico patient study
15, 1447938
DOI 10.3389/fphys.2024.1447938, PubMed 39224207
Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum
45 (20), 1831-1839
DOI 10.1093/eurheartj/ehae224, PubMed 38740526
Publications 2023
Lifetime exercise dose and ventricular arrhythmias in patients with mitral valve prolapse
25 (10)
DOI 10.1093/europace/euad309, PubMed 37851515
Sudden cardiac death in the young-Can illicit drug use explain the unexplained?
20 (10), 1356-1357
DOI 10.1016/j.hrthm.2023.06.014, PubMed 37352948
The added value of abnormal regional myocardial function for risk prediction in arrhythmogenic right ventricular cardiomyopathy
24 (12), 1710-1718
DOI 10.1093/ehjci/jead174, PubMed 37474315
Monitoring of Myocardial Involvement in Early Arrhythmogenic Right Ventricular Cardiomyopathy Across the Age Spectrum
82 (9), 785-797
DOI 10.1016/j.jacc.2023.05.065, PubMed 37612010
Publications 2022
Pregnancy and Progression of Cardiomyopathy in Women With LMNA Genotype-Positive
11 (8), e024960
DOI 10.1161/JAHA.121.024960, PubMed 35434999
The response to cardiac resynchronization therapy in LMNA cardiomyopathy
24 (4), 685-693
DOI 10.1002/ejhf.2463, PubMed 35229420
Progression of cardiac disease in patients with lamin A/C mutations
23 (4), 543-550
DOI 10.1093/ehjci/jeab057, PubMed 33824984
Publications 2021
Sex differences in disease progression and arrhythmic risk in patients with arrhythmogenic cardiomyopathy
23 (7), 1084-1091
DOI 10.1093/europace/euab077, PubMed 33829244
Publications 2020
Pregnancies, ventricular arrhythmias, and substrate progression in women with arrhythmogenic right ventricular cardiomyopathy in the Nordic ARVC Registry
22 (12), 1873-1879
DOI 10.1093/europace/euaa136, PubMed 32681178
Absence of ECG Task Force Criteria does not rule out structural changes in genotype positive ARVC patients
317, 152-158
DOI 10.1016/j.ijcard.2020.05.095, PubMed 32504717
Reply to: TFC ECG in arrhythmogenic cardiomyopathy: Inadequate mixture of criteria?
323, 203
DOI 10.1016/j.ijcard.2020.08.050, PubMed 32810539
Publications 2019
Number of pregnancies and subsequent phenotype in a cross-sectional cohort of women with arrhythmogenic cardiomyopathy
20 (2), 192-198
DOI 10.1093/ehjci/jey061, PubMed 29659777